PR95400

BEIJING, April 8, 2022 /PRNewswire=KYODO JBN/ --

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that they have reached

an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ code: BGNE;

Hong Kong Stock Exchange code: 06160; Shanghai Stock Exchange code: 688235) on

March 10, for licensing of Biocytogen's fully human antibody

RenMab(TM)/RenLite(TM) mice platform with proprietary intellectual property

rights of Biocytogen to develop fully human monoclonal antibodies, bispecific

antibodies and other types of antibody drugs.

RenMab(TM) and RenLite(TM) was developed by Biocytogen over 5 years using

SUPCE, a size-unlimited, precise chromosome engineering technology. In

RenMab(TM) mice, the whole mouse variable regions of the heavy and kappa light

chains were replaced by full human heavy chain VDJ segment and light chain VJ

loci in situ; In RenLite(TM) mice, the whole mouse variable regions of the

heavy chain were replaced with full human heavy chain VDJ segment in situ, and

the whole mouse variable regions of the e light chain was replaced with a

single human e light chain VJ loci in situ. RenMab(TM)/RenLite(TM) mice can

generate fully human antibody candidates with high affinity, specificity, and

diversity for downstream antibody drug screening. Meanwhile, the common light

chain antibodies generated by RenLite(TM) mice can greatly improve the

efficiency of downstream assembly of complex drug molecules such as bispecific

antibodies.

BeiGene is a global, science-driven biotechnology company focused on developing

innovative and affordable medicines to improve treatment outcomes and access

for patients worldwide. BeiGene currently has three approved medicines

discovered and developed in our own labs: BTK inhibitor BRUKINSA in the United

States, China, the EU and Great Britain, Canada, Australia and additional

international markets; and the non-FC-gamma receptor binding anti-PD-1 antibody

tislelizumab as well as the PARP inhibitor pamiparib in China. BeiGene has

established a number of internal technology platforms, including small molecule

drug development platform, proteolysis targeting chimera (CDAC) technology

platform and bispecific (multispecific) antibody discovery platform, single

B-cell antibody screening platform and antibody-drug conjugate (ADC)

development platform.

For this collaboration, Dr. Yuelei Shen, Founder and CEO of Biocytogen, says

"As one of the leading fully human antibody discovery platforms, Biocytogen's

RenMab(TM)/RenLite(TM) will provide strong support in drug development of

challenging targets. Meanwhile, RenLite(TM) mice can generate bispecific

antibodies with simple monoclonal antibody structures, reducing the difficulty

of subsequent drug conjugation and opening more possibilities for innovative

drug development."

Dr. Lai Wang, Senior Vice President and Global Head of R&D of BeiGene, says

"BeiGene has always been focused on developing differentiated innovative drugs

and the application of innovative technologies. It is hoped that licensing of

RenMab(TM)/RenLite(TM) mice platform will help us enrich the innovative drugs

development path by exploring innovative targets and contribute to our vision

of "Transform the biotechnology industry, creating impactful medicines that

will be affordable and accessible to far more cancer patients around the world."

About Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotech company that

drives the research and development of novel antibody-based drugs with

innovative technologies. The company is committed to becoming a global

headstream of new drugs and bringing benefits to patients around the world.

Based on the proprietary fully human antibody RenMab(TM) and RenLite(TM) mice,

Biocytogen has integrated its monoclonal and bispecific antibody development

platforms, in vivo drug efficacy screening platforms and strong clinical

development ability to streamline the entire drug development process.

Biocytogen is undertaking a large-scale project to develop antibody drugs for

more than 1000 potential druggable targets known as Project Integrum. With the

implementation of Project Integrum, Biocytogen has entered collaboration with

dozens of partners worldwide and will continue such collaboration to produce a

variety of first-in-class and/or best-in-class antibody drugs to benefit

patients. Currently, the company has established a pipeline of 12 core

products, among which 2 products are at phase II multi-regional clinical trial

(MRCT) and 2 products are at phase I. Headquartered in Beijing, Biocytogen has

branches in Haimen Jiangsu, Shanghai and Boston, USA.

About BeiGene

BeiGene is a global, science-driven biotechnology company focused on developing

innovative and affordable medicines to improve treatment outcomes and access

for patients worldwide. With a broad portfolio of more than 40 clinical

candidates, we are expediting development of our diverse pipeline of novel

therapeutics through our own capabilities and collaborations. We are committed

to radically improving access to medicines for two billion more people by 2030.

BeiGene has a growing global team of over 8,000 colleagues across five

continents. To learn more about BeiGene, please visit www.beigene.com and

follow us on Twitter at @BeiGeneGlobal.

Source:Biocytogen

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=418816